Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia with Novel Targeted Agents

por Cheson, Bruce D., Heitner Enschede, Sari, Cerri, Elisa, Desai, Monali, Potluri, Jalaja, Lamanna, Nicole, Tam, Constantine
Publicado 2017

P521: FINDINGS FROM AN ANALYSIS OF PATIENTS WITH MONOCYTIC AND MONOCYTIC-LIKE ACUTE MYELOID LEUKEMIA (AML), INCLUDING AML-M4 AND AML-M5, TREATED WITH VENETOCLAX (VEN) PLUS AZACITID...

por Konopleva, Marina, D. Dinardo, Courtney, Sun, Yan, Loghavi, Sanam, Jung, Paul, Potluri, Jalaja, Dail, Monique, Chyla, Brenda, A. Pollyea, Daniel
Publicado 2023

S310: VENETOCLAX PLUS AZACITIDINE DELAYS DETERIORATION OF HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA: VIALE-A LONG-TERM FOLLOW UP

por Pratz, Keith, Lai, Catherine, Jonas, Brian A., Dinardo, Courtney, Bui, Cat N., Kamalakar, Rajesh, Potluri, Jalaja, Chang, Wei-Han, Sen, Rohini, Leblanc, Thomas W
Publicado 2023

P525: LONG-TERM OUTCOMES OF STEM CELL TRANSPLANT IN OLDER PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED WITH VENETOCLAX + HMA THERAPIES

por Pratz, Keith, Dinardo, Courtney, L Arellano, Martha, Thirman, Michael, Pullarkat, Vinod, S. Becker, Pamela, Douglas Smith, B., Zhang, Meng, E Werner, Michael, Potluri, Jalaja, A. Pollyea, Daniel
Publicado 2023

Venetoclax exposure‐efficacy and exposure‐safety relationships in patients with treatment‐naïve acute myeloid leukemia who are ineligible for intensive chemotherapy

por Brackman, Deanna, Eckert, Doerthe, Menon, Rajeev, Salem, Ahmed Hamed, Potluri, Jalaja, Smith, B. Douglas, Wei, Andrew H., Hayslip, John, Miles, Dale, Mensing, Sven, Gopalakrishnan, Sathej, Zha, Jiuhong
Publicado 2022

Venetoclax for chronic lymphocytic leukaemia patients who progress after more than one B‐cell receptor pathway inhibitor

por Wierda, William G., Byrd, John C., Davids, Matthew S., Furman, Richard R., Cheson, Bruce D., Barr, Paul M., Eradat, Herbert, Heffner, Leonard, Zhou, Lang, Verdugo, Maria, Potluri, Jalaja, Choi, Michael
Publicado 2018

Genetic biomarkers of sensitivity and resistance to venetoclax monotherapy in patients with relapsed acute myeloid leukemia

por Chyla, Brenda, Daver, Naval, Doyle, Kelly, McKeegan, Evelyn, Huang, Xin, Ruvolo, Vivian, Wang, Zixing, Chen, Ken, Souers, Andrew, Leverson, Joel, Potluri, Jalaja, Boghaert, Erwin, Bhathena, Anahita, Konopleva, Marina, Popovic, Relja
Publicado 2018

Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine

por Pollyea, Daniel A., Pratz, Keith W., Wei, Andrew H., Pullarkat, Vinod, Jonas, Brian A., Recher, Christian, Babu, Sunil, Schuh, Andre C., Dail, Monique, Sun, Yan, Potluri, Jalaja, Chyla, Brenda, DiNardo, Courtney D.
Publicado 2022

Impact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia

por Konopleva, Marina, Thirman, Michael J., Pratz, Keith W., Garcia, Jacqueline S., Recher, Christian, Pullarkat, Vinod, Kantarjian, Hagop M., DiNardo, Courtney D., Dail, Monique, Duan, Yinghui, Chyla, Brenda, Potluri, Jalaja, Miller, Catherine L., Wei, Andrew H.
Publicado 2022

Use of CYP3Ai and impact on outcomes in patients with acute myeloid leukemia treated with venetoclax plus azacitidine in the VIALE‐A study

por Jonas, Brian A., DiNardo, Courtney, Fracchiolla, Nicola, Pristupa, Alexander, Ishizawa, Kenichi, Jin, Jie, Konopleva, Marina, Ofran, Yishai, Montesinos, Pau, Kovacsovics, Tibor, Jang, Jun‐Ho, Kantarjian, Hagop, Duan, Yinghui, Potluri, Jalaja, Werner, Michael, Pratz, Keith W.
Publicado 2022

P418: DELE1 LOSS AND DYSFUNCTIONAL INTEGRATED STRESS SIGNALING IN TP53 MUTATED AML IS A NOVEL PATHWAY FOR VENETOCLAX RESISTANCE

por Sharon, David, Jung, Paul, Sun, Yan, Feng, Weiguo, Yang, Ziping, Robinson, Valerie, Mitra, Diya, Liu, Wei, Zheng, Pingping, Uziel, Tami, Lam, Lloyd, Minden, Mark, Ross, Jeremy, Mendes, Wellington, Potluri, Jalaja, Wei, Andrew, Konopleva, Marina, Dail, Monique, Chyla, Brenda, Epling-Burnette, Pk
Publicado 2023

Utility of positron emission tomography-computed tomography in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapy

por Mato, Anthony R., Wierda, William G., Davids, Matthew S., Cheson, Bruce D., Coutre, Steven E., Choi, Michael, Furman, Richard R., Heffner, Leonard, Barr, Paul M., Eradat, Herbert, Ford, Sharanya M., Zhou, Lang, Verdugo, Maria, Humerickhouse, Rod A., Potluri, Jalaja, Byrd, John C.
Publicado 2019

Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia and IDH1/2 Mutations

por Pollyea, Daniel A., DiNardo, Courtney D., Arellano, Martha L., Pigneux, Arnaud, Fiedler, Walter, Konopleva, Marina, Rizzieri, David A., Smith, B. Douglas, Shinagawa, Atsushi, Lemoli, Roberto M., Dail, Monique, Duan, Yinghui, Chyla, Brenda, Potluri, Jalaja, Miller, Catherine L., Kantarjian, Hagop M.
Publicado 2022

Timing of response with venetoclax combination treatment in patients with newly diagnosed acute myeloid leukemia

por Jonas, Brian A., Wei, Andrew H., Recher, Christian, DiNardo, Courtney D., Jang, Jun‐Ho, Pratz, Keith, Panayiotidis, Panayiotis, Montesinos, Pau, Yeh, Su‐Peng, Ivanov, Vladimir, Fiedler, Walter, Yamauchi, Takahiro, Duan, Yinghui, Mendes, Wellington, Potluri, Jalaja, Tews, Björn, Ofran, Yishai
Publicado 2022

A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes

por Zeidan, Amer M., Borate, Uma, Pollyea, Daniel A., Brunner, Andrew M., Roncolato, Fernando, Garcia, Jacqueline S., Filshie, Robin, Odenike, Olatoyosi, Watson, Anne Marie, Krishnadasan, Ravitharan, Bajel, Ashish, Naqvi, Kiran, Zha, Jiuhong, Cheng, Wei‐Han, Zhou, Ying, Hoffman, David, Harb, Jason G., Potluri, Jalaja, Garcia‐Manero, Guillermo
Publicado 2022

Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine

por Pratz, Keith W., Jonas, Brian A., Pullarkat, Vinod, Recher, Christian, Schuh, Andre C., Thirman, Michael J., Garcia, Jacqueline S., DiNardo, Courtney D., Vorobyev, Vladimir, Fracchiolla, Nicola S., Yeh, Su-Peng, Jang, Jun Ho, Ozcan, Muhit, Yamamoto, Kazuhito, Illes, Arpad, Zhou, Ying, Dail, Monique, Chyla, Brenda, Potluri, Jalaja, Döhner, Hartmut
Publicado 2022

Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients With Myelofibrosis With Progression or Suboptimal Response: Phase II Safety and Efficacy

por Harrison, Claire N., Garcia, Jacqueline S., Somervaille, Tim C.P., Foran, James M., Verstovsek, Srdan, Jamieson, Catriona, Mesa, Ruben, Ritchie, Ellen K., Tantravahi, Srinivas K., Vachhani, Pankit, O'Connell, Casey L., Komrokji, Rami S., Harb, Jason, Hutti, Jessica E., Holes, Leanne, Masud, Abdullah A., Nuthalapati, Silpa, Potluri, Jalaja, Pemmaraju, Naveen
Publicado 2022

Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy

por Yamamoto, Kazuhito, Shinagawa, Atsushi, DiNardo, Courtney D, Pratz, Keith W, Ishizawa, Kenichi, Miyamoto, Toshihiro, Komatsu, Norio, Nakashima, Yasuhiro, Yoshida, Chikashi, Fukuhara, Noriko, Usuki, Kensuke, Yamauchi, Takahiro, Asada, Noboru, Asou, Norio, Choi, Ilseung, Miyazaki, Yasushi, Honda, Hideyuki, Okubo, Sumiko, Kurokawa, Misaki, Zhou, Ying, Zha, Jiuhong, Potluri, Jalaja, Matsumura, Itaru
Publicado 2021

Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia

por Pratz, Keith W., Panayiotidis, Panayiotis, Recher, Christian, Wei, Xudong, Jonas, Brian A., Montesinos, Pau, Ivanov, Vladimir, Schuh, Andre C., DiNardo, Courtney D., Novak, Jan, Pejsa, Vlatko, Stevens, Don, Yeh, Su-Peng, Kim, Inho, Turgut, Mehmet, Fracchiolla, Nicola, Yamamoto, Kazuhito, Ofran, Yishai, Wei, Andrew H., Bui, Cat N., Benjamin, Katy, Kamalakar, Rajesh, Potluri, Jalaja, Mendes, Wellington, Devine, Jacob, Fiedler, Walter
Publicado 2022